Research programme: A3 adenosine receptor agonists - Can-Fite BioPharma

Drug Profile

Research programme: A3 adenosine receptor agonists - Can-Fite BioPharma

Alternative Names: A3 adenosine receptor allosteric modulators - Can-Fite BioPharma; CF 402; CF-402 - Can-Fite BioPharma; CF-502; CF-602

Latest Information Update: 10 Nov 2016

Price : $50

At a glance

  • Originator Can-Fite BioPharma; Leiden University; National Institutes of Health (USA)
  • Developer Can-Fite BioPharma
  • Class Amides; Cyclohexanes; Quinolines; Small molecules
  • Mechanism of Action Adenosine A3 receptor agonists; Nitric oxide stimulants; Vascular endothelial growth factors stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Inflammation; Sexual function disorders

Most Recent Events

  • 09 Nov 2016 Can-Fite BioPharm receives patent allowance for CF 602 in USA
  • 19 Jan 2016 Can-Fite receives patent allowance for CF602 in USA
  • 29 Jun 2015 Pharmacodynamics data from a preclinical study in Sexual function disorders released by Can-Fite BioPharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top